UMUna Macleod

Una Macleod

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Una Macleod has a total of 90 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Are there inequalities in colon cancer diagnosis and treatment in England? A population-based study

    by Benjamin Alexander Pickwell-Smith, Lewis William Paton, Ireneous Soyiri, Michael Lind, Una Macleod

    IntroductionSocioeconomic inequalities in cancer outcomes persist across many high-income countries, including those with universal healthcare systems. Evidence suggests that patients from more deprived populations may experience differences in access to cancer treatment and diagnostic pathways. This study examined socioeconomic variation in treatment receipt and diagnostic and treatment intervals among patients with colon cancer in England.MethodsA population-based cohort study using National Cancer Registry Data for individuals diagnosed with colon cancer in England between 2016 and 2017. Registry data were linked to multiple administrative datasets - Hospital Episode Statistics, Cancer Pathway, Systematic Anti-Cancer Dataset, and Diagnostic Imaging Dataset - to obtain information on treatments, comorbidity, route to diagnosis, and diagnostic and treatment intervals. Quintiles of the Index of Multiple Deprivation measured deprivation. Multivariable logistic regression examined associations between deprivation and receipt of surgery, adjuvant chemotherapy for stage II-III, and chemotherapy for stage IV disease. Quantile regression assessed differences in diagnostic and treatment intervals. All analyses were conducted using Stata v17. The study was registered on ClinicalTrials.gov (NCT05185388).ResultsPatients living in the most deprived quintile had significantly reduced odds of surgery (OR 0.62, 95% CI 0.56-0.69). Similar inequalities were observed for adjuvant chemotherapy in stage II-III disease (OR 0.73, 95% 0.65-0.83) and for chemotherapy in stage IV disease (OR 0.63, 95% CI 0.54-0.74). Diagnostic and treatment intervals were modestly longer among patients from more deprived areas, with adjusted differences of approximately 2-5 days at the median and upper quartiles.ConclusionSocioeconomic inequalities in colon cancer diagnosis and treatment persist in England despite the presence of a universal healthcare system. Patients from more deprived areas were less likely to receive potentially beneficial treatments and experienced modestly longer diagnostic and treatment intervals. These finding suggest persistent structural and systemic barriers within the healthcare pathway that require targeted policy and service-level interventions.

  • Open Access

    Internet and telephone intervention to support patients discontinuing long-term antidepressants in primary care: the REDUCE research programme including RCT

    by Tony Kendrick, Beth Stuart, Hannah Bowers, Mahboobeh Haji Sadeghi, Helen Page, Christopher Dowrick, Michael Moore, Mark Gabbay, Geraldine Leydon, Guiqing Lily Yao, et al.

    Background: There is significant concern about increasing long-term antidepressant use in Western countries, much of which is not evidence-based. Median duration of treatment is more than 2 years in the United Kingdom, and more than 10% of adults are taking antidepressants, risking potentially significant adverse effects, particularly for older patients. Objectives: To develop internet- and telephone-based support for practitioners and patients, through a process of co-design, and to determine its effectiveness and cost-effectiveness in helping people discontinue antidepressants without increasing depression, in a randomised controlled trial. Design: Two systematic reviews (one qualitative); qualitative interviews with patients; qualitative interviews and focus groups with healthcare practitioners; co-production of online interventions with patients and practitioners; feasibility randomised controlled trial; definitive non-inferiority cluster randomised controlled trial with health economic evaluation; and quantitative and qualitative process evaluations. A booklet and video version of the patient intervention was also developed in Urdu. Setting: Primary care (131 general practices in England and Wales). Participants: Adults on antidepressant treatment for more than 1 year for a first episode of depression, or more than 2 years for recurrent depression, who were no longer depressed or judged to be at significant risk of relapse. Interventions: Tailored internet support (ADvisor for patients, and ADvisorHP for health professionals), plus three telephone support calls from psychological well-being practitioners. Primary outcome: Depressive symptoms on the Patient Health Questionnaire-9 items questionnaire at 6 months. Secondary outcomes: Depressive symptoms over 12 months, antidepressant discontinuation, anxiety, quality of life, withdrawal symptoms, adverse events, mental well-being, patient enablement, patient satisfaction, health service use and costs over 12 months. Sample size: The original sample size calculation gave a target of 402 patients for 90% power with one-sided significance of 2.5% to determine non-inferiority of the intervention, within 2 points on the Patient Health Questionnaire-9 items. This was reduced to 360 on finding a significant correlation between baseline and follow-up values for the Patient Health Questionnaire-9 items part-way through the trial. Randomisation: Remote cluster randomisation of practices by computerised sequence generation, with minimisation by practice size, urban/rural location and deprivation index. Blinding: Participants and researchers could not be blinded given the pragmatic open design, but self-complete measures avoided observer rating bias, and analyses were conducted blind. Analyses: Linear mixed modelling was used to determine differences in outcomes, adjusting for previous depression, baseline outcome values, baseline anxiety, sociodemographic characteristics, and practice as a random effect. Primary analysis was performed by intention to treat, with per-protocol and complier-average sensitivity analyses. Multiple imputation was used to account for missing values. Qualitative interviews: Semistructured topic guides were used for interviews and focus groups, informed by normalisation process theory, which were audio-recorded, transcribed verbatim and analysed using reflexive thematic analysis. Results: Systematic reviews, qualitative interviews and focus groups indicated that barriers to discontinuing treatment include a fear of relapse of depression and withdrawal symptoms. If practitioners do not broach possible discontinuation, patients will usually continue treatment without questioning it. Patients wanted information on antidepressant mechanisms and effects, withdrawal symptoms and coping strategies. Practitioners wanted guidance on initiating discontinuation, antidepressant tapering regimens, and distinguishing withdrawal from relapse. The definitive trial randomised 330 patients (5% of those approached; 178 in intervention practices and 152 in controls), of whom 275 (83%) were followed up at 6 months, and 240 (73%) at 12 months. Mean Patient Health Questionnaire-9 items scores were slightly higher among controls at 6 months [5.0 vs. 4.0; adjusted difference 1.07 (95% confidence interval 0.09 to 2.06; p = 0.033)]. Antidepressant discontinuation rates at 6 months were slightly higher in the intervention arm, but not significantly (45.5% vs. 41.9% in the control arm). Antidepressant withdrawal symptoms and mental well-being were significantly better in the intervention arm. There were no significant differences in anxiety, quality of life, adverse events, patient enablement, or satisfaction with care. The adjusted mean cost of services used was lower in the intervention arm by −£69 (95% confidence interval −£77 to £207). The incremental cost-effectiveness ratio was a mean saving of −£2839 per quality-adjusted life-year gained (95% confidence interval −£30,024 to £22,227). The probability of the intervention being cost-effective compared to review alone, at the National Institute for Health and Care Excellence thresholds of societal willingness to pay of £20,000 and £30,000 per quality-adjusted life-year, was > 89% for both. Qualitative interviews suggested advice to taper slowly, and information on the difference between relapse and withdrawal symptoms, contributed significantly to the success of the interventions. Participants were well and willing to attempt antidepressant discontinuation, and general practitioners excluded people considered at high risk of relapse of depression. This may explain why more than 40% of participants in each arm discontinued. The results may not generalise to an unselected sample of people on long-term antidepressants, including people at greater risk of relapse. Conclusions: Comparatively high rates of discontinuation of long-term antidepressants are achievable through enabling patients, who are ready to consider stopping them, to get tapering advice and support from their general practitioners. Tailored internet and psychologist telephone support may help protect patients coming off long-term antidepressants against depressive and withdrawal symptoms, and conserve mental well-being. The interventions appear highly cost-effective at thresholds for societal willingness to pay used by the National Institute for Health and Care Excellence. Trial registration: Workstream 4 (feasibility trial) is registered as International Standardised Randomised Controlled Trial Number ISRCTN15036829 and Workstream 5 (definitive trial of effectiveness and cost-effectiveness) is registered as ISRCTN12417565. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research programme (NIHR award ref: RP-PG-1214-20004) and is published in full in Programme Grants for Applied Research; Vol. 13, No. 7. See the NIHR Funding and Awards website for further award information.

  • Open Access

    GP referral to rapid diagnostic centres for non-specific cancer symptoms: a qualitative study

    by Caroline White, Spencer Robinson, Una Macleod, Charlotte Kelly

    Background: Diagnosing cancer can be challenging, especially when patients present to GPs with serious, but non-specific symptoms. Rapid diagnostic centres (RDCs) have been introduced in England as diagnostic pathways for patients with non-specific symptoms where cancer is suspected, but they do not meet existing cancer pathway criteria. Aim: To investigate GP perspectives on referral to an RDC pathway for patients with non-specific symptoms and suspected cancer. Design & setting: A qualitative study using semi-structured interviews with GPs, within the catchment area of an acute NHS trust in the UK. Method: GP interviews focusing on experiences of using the RDC pathway. A thematic analysis was conducted on interview transcripts. Results: GPs reported the RDC pathway as a game changer. It offered faster referral, reduced anxiety for GPs and patients, and reduced the need for GPs to ‘ game the system ’ when patients do not meet criteria for cancer-specific pathways. The narrative required on referral appeared to legitimise GP gut feelings and expertise. RDC results (if not cancer) gave GPs space to treat patients without concern of a missed cancer, while ensuring onward referral for those with cancer or other serious conditions. Some access barriers, especially related to travel and time, were identified especially for patients in rural areas. Conclusion: This cancer pathway fills a referral gap for GPs and patients with non-specific potential cancer symptoms. It has an important signposting function, helping identify patients requiring treatment for cancer or other serious conditions, and others whose symptoms can be treated safely within primary care.


  • Open Access

    Challenges and opportunities for cervical screening in women over the age of 50 years: a qualitative study

    by Alison Bravington, Hong Chen, Judith Dyson, Lesley Jones, Christopher Dalgliesh, Amée Bryan, Julietta Patnick, Una Macleod

    Background: Cervical cancer is a preventable disease. Cases in women age >50 years are predicted to rise by 60% in the next two decades, yet this group are less likely to attend for screening than younger women.Aim: To seek novel solutions to the challenges of cervical screening in women >50 years of age by examining practitioner and service-user experiences.Design and setting: Semi-structured interviews were conducted with 28 practitioners and 24 service users >50 years of age, recruited via UK primary care networks in Northern England in 2016–2017, to explore experiences related to cervical screening.Method: An inductive thematic analysis was conducted to explore the data.Results: Findings are presented under three key themes. The first,exploring the barriers to successful cervical screening, examines the influences of sexuality and early experiences of screening on attendance, and how preventive health care becomes a low priority as women age. The second,the role of relationships, explores how peer talk shapes attitudes towards cervical screening, how teamwork between practitioners engenders investment in cervical screening, and how interactions between service users and primary care over time can significantly affect intentions to screen. The third,what constitutes good practice, describes practical and sensitive approaches to screening tailored to women aged >50 years.Conclusion: Good practice involves attention to structural and practical challenges, and an understanding of the role of relationships in shaping screening intentions. Experienced practitioners adapt procedures to increase sensitivity, and balance time invested in problem solving against the benefits of reaching practice targets for attendance. Building networks of expertise across multiple practices can increase practitioner skill in screening this age group.


  • Open Access

    Rapid review of factors associated with flexible sigmoidoscopy screening use

    by Robert S. Kerrison, Christian von Wagner, Trish Green, Monica Gibbins, Una Macleod, Mark Hughes, Colin J. Rees, Stephen Duffy, Lesley M. McGregor


  • Open Access

    Lung cancer symptom appraisal among people with chronic obstructive pulmonary disease: A qualitative interview study

    by Yvonne Cunningham, Sally Wyke, Kevin G. Blyth, Douglas Rigg, Sara Macdonald, Una Macleod, Stephen Harrow, Kathryn A. Robb, Katriina L. Whitaker

    Objective: The incidence of lung cancer is four times higher in people with chronic obstructive pulmonary disease (COPD) compared with the general population. Promotion of a shorter time from symptom onset to presentation is one potential strategy for earlier lung cancer diagnosis, but distinguishing respiratory symptoms can be difficult. We investigated how the experience of COPD influences symptom appraisal and help seeking for potential lung cancer symptoms.Methods: We conducted qualitative interviews with men (n = 17) and women (n = 23) aged 40 to 83 years with COPD. Topic guides drew on the integrated symptom‐response framework and covered symptom experience, interpretation, action, recognition, help seeking, evaluation, and reevaluation. We used the framework method to analyse the data.Results: Participants said that they attributed chest symptoms to their COPD; no other cause was considered. Participants said that family/friends noticed changes in their symptoms and encouraged help seeking. Others felt isolated by their COPD because they could not get out, were fatigued, or were embarrassed. Participants visited health professionals frequently, but increased risk of lung cancer was not discussed.Conclusions: Our study provides insight into different levels of influence on symptom appraisal and targets for intervention. Greater awareness of increased lung cancer risk and support to act on symptom changes is essential and could be achieved through a concerted information campaign. Health professionals working with people with COPD could also optimise appointments to support symptom appraisal of potential lung cancer symptoms.


  • Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT

    by David Kessler, Alison Burns, Debbie Tallon, Glyn Lewis, Stephanie MacNeill, Jeff Round, William Hollingworth, Carolyn Chew-Graham, Ian Anderson, John Campbell, et al.

    Background: Depression is usually managed in primary care and antidepressants are often the first-line treatment, but only half of those treated respond to a single antidepressant. Objectives: To investigate whether or not combining mirtazapine with serotonin–noradrenaline reuptake inhibitor (SNRI) or selective serotonin reuptake inhibitor (SSRI) antidepressants results in better patient outcomes and more efficient NHS care than SNRI or SSRI therapy alone in treatment-resistant depression (TRD). Design: The MIR trial was a two-parallel-group, multicentre, pragmatic, placebo-controlled randomised trial with allocation at the level of the individual. Setting: Participants were recruited from primary care in Bristol, Exeter, Hull/York and Manchester/Keele. Participants: Eligible participants were aged ≥ 18 years; were taking a SSRI or a SNRI antidepressant for at least 6 weeks at an adequate dose; scored ≥ 14 points on the Beck Depression Inventory-II (BDI-II); were adherent to medication; and met the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, criteria for depression. Interventions: Participants were randomised using a computer-generated code to either oral mirtazapine or a matched placebo, starting at a dose of 15 mg daily for 2 weeks and increasing to 30 mg daily for up to 12 months, in addition to their usual antidepressant. Participants, their general practitioners (GPs) and the research team were blind to the allocation. Main outcome measures: The primary outcome was depression symptoms at 12 weeks post randomisation compared with baseline, measured as a continuous variable using the BDI-II. Secondary outcomes (at 12, 24 and 52 weeks) included response, remission of depression, change in anxiety symptoms, adverse events (AEs), quality of life, adherence to medication, health and social care use and cost-effectiveness. Outcomes were analysed on an intention-to-treat basis. A qualitative study explored patients’ views and experiences of managing depression and GPs’ views on prescribing a second antidepressant. Results: There were 480 patients randomised to the trial (mirtazapine and usual care, n = 241; placebo and usual care, n = 239), of whom 431 patients (89.8%) were followed up at 12 weeks. BDI-II scores at 12 weeks were lower in the mirtazapine group than the placebo group after adjustment for baseline BDI-II score and minimisation and stratification variables [difference –1.83 points, 95% confidence interval (CI) –3.92 to 0.27 points; p = 0.087]. This was smaller than the minimum clinically important difference and the CI included the null. The difference became smaller at subsequent time points (24 weeks: –0.85 points, 95% CI –3.12 to 1.43 points; 12 months: 0.17 points, 95% CI –2.13 to 2.46 points). More participants in the mirtazapine group withdrew from the trial medication, citing mild AEs (46 vs. 9 participants). Conclusions: This study did not find convincing evidence of a clinically important benefit for mirtazapine in addition to a SSRI or a SNRI antidepressant over placebo in primary care patients with TRD. There was no evidence that the addition of mirtazapine was a cost-effective use of NHS resources. GPs and patients were concerned about adding an additional antidepressant. Limitations: Voluntary unblinding for participants after the primary outcome at 12 weeks made interpretation of longer-term outcomes more difficult. Future work: Treatment-resistant depression remains an area of important, unmet need, with limited evidence of effective treatments. Promising interventions include augmentation with atypical antipsychotics and treatment using transcranial magnetic stimulation. Trial registration: Current Controlled Trials ISRCTN06653773; EudraCT number 2012-000090-23. Funding: This project was funded by the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 63. See the NIHR Journals Library website for further project information.


  • What predicts patient non-attendance at urgent referral appointments for suspected cancer?

    by Rebecca Sheridan, Steven Oliver, Lisa Dyson, Victoria Allgar, Karl Atkin, Trish Green, Geoff Hall, Una Macleod, Philip Melling, Martin Waugh, et al.


  • Open Access

    In search of the cancer candidate: can lay epidemiology help?

    by Sara Macdonald, Graham Watt, Una Macleod

    First published in 1991, the ideas embedded in ‘Lay epidemiology and the prevention paradox’ offered a novel and rational explanation for the lay public’s failure to fully engage with the lifestyle messages offered by health educators. During the course of a large ethnographic study in South Wales, Davison and colleagues described the emergence of what they termed the coronary candidate. Candidacy provides a ‘cultural mechanism’ that facilitates the estimation of risk for coronary heart disease. The model has rarely been applied to other major illnesses. This article presents findings from a study that sought to explore the lay epidemiology model, candidacy and cancer. In a series of in‐depth individual interviews, members of the lay public discussed their ideas about cancer, and what emerged was an explanatory hierarchy to account for cancer events. Yet the random and unpredictable nature of cancer was emphasised as well as a general reluctance to accept the idea of cancer candidacy.